Literature DB >> 12011650

Soluble Fas ligand and atherosclerosis in hypertensive patients.

Takafumi Okura1, Sanae Watanabe, Yinong Jiang, Michitsugu Nakamura, Yasunori Takata, Zhao-Hui Yang, Katsuhiko Kohara, Yutaka Kitami, Kunio Hiwada.   

Abstract

BACKGROUND: The Fas-Fas ligand (FasL) system is involved in apoptosis in many types of cells. Recently, the expression of FasL on endothelial cells was reported. FasL is cleaved by a metalloproteinase and released in serum as soluble FasL (sFasL). Vasoactive substances, including metalloproteinase, are modulated by endothelial dysfunction. Advanced atherosclerosis and impaired endothelial function are seen in hypertensive patients. The inflammatory response has an important role in the development of atherosclerosis, whereas C-reactive protein (CRP) is associated with the presence and severity of atherosclerosis.
OBJECTIVE: To measure the intima-media thickness of the common carotid artery and evaluate the relationship between atherosclerosis and serum sFasL concentrations in hypertensive patients. PATIENTS AND MAIN OUTCOME MEASURES: Forty-seven patients with hypertension participated in the study. The intima-media thickness of the common carotid artery was evaluated by ultrasound imaging. Serum concentrations of sFasL were measured by enzyme-linked immunosorbent assay.
RESULTS: Intima-media thickness correlated positively with age (r = 0.362, P = 0.012) and sFasL concentrations (r =0.332, P = 0.022), and negatively with creatinine clearance (r = -0.399, P = 0.0055). A general linear model analysis with atherosclerotic risk factors and sFasL revealed that age, sFasL, high-density lipoprotein-cholesterol and systolic blood pressure were significantly associated with intima-media thickness. Furthermore, we demonstrated that serum sFasL is directly associated with CRP concentration (r = 0.316, P = 0.030).
CONCLUSIONS: These results indicated that serum sFasL concentration is associated with atherosclerosis and inflammatory disease, in patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12011650     DOI: 10.1097/00004872-200205000-00024

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  3 in total

1.  The Relationship of Serum Soluble Fas Ligand (sFasL) Level with the Extent of Coronary Artery Disease.

Authors:  Asife Sahinarslan; Bulent Boyaci; Sinan Altan Kocaman; Salih Topal; Ugur Ercin; Kaan Okyay; Neslihan Bukan; Ridvan Yalçin; Atiye Cengel
Journal:  Int J Angiol       Date:  2012-03

2.  Increased serum concentrations of soluble CD95/Fas and caspase 1/ICE in patients with acute angina.

Authors:  H J Ankersmit; T Weber; J Auer; G Roth; M Brunner; E Kvas; B Moser; S Spreitzer; E Lassnig; E Maurer; P Hartl; E Wolner; G Boltz-Nitulescu; B Eber
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

3.  Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis.

Authors:  Wan-Uk Kim; Seung-Ki Kwok; Kyung-Hee Hong; Seung-Ah Yoo; Jin-Sun Kong; Jongseon Choe; Chul-Soo Cho
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.